A new foundation that connects clinical data, evidence, process knowledge, and decision rights, enabling AI agents to work with explainable, auditable, and role-appropriate context.
EDISON, N.J.–(BUSINESS WIRE)–#AIGovernance—Maxis AI today introduced MaxisAI Holarchy, its Verticalized Context Layer, a governed institutional memory that gives life sciences enterprises the trusted organizational context AI agents need to support clinical execution across the development lifecycle. It sits between every AI agent and every model; grounds each call in the standards, compliance, and policies an organization runs on; checks it against the rules its regulator enforces; and seals the whole path into an inspection-ready record. It is available as an independent product or within the MaxisAI platform.
As life sciences organizations move beyond isolated AI assistants, a critical gap has emerged. Agents can generate content and execute tasks, but they often lack a consistent understanding of the protocol, operational state, source data, evidence provenance, policies, and human decision rights that define how work should be performed. MaxisAI Holarchy connects that context, knowledge, controls, and evidence into a reusable foundation for agentic work.
“The next era of AI in clinical development will not be defined by how many agents an organization runs. It will be defined by whether those agents can act with the right context, within the right guardrails, and with clear accountability,” said Moulik Shah, Founder and CEO of Maxis AI. “The Context Layer gives organizations a way to transform fragmented information into a governed institutional memory so that AI agents can help teams move faster while preserving trust, transparency, and human oversight.”
In regulated work, a fluent answer is not enough. An inspection asks who approved an output, on what basis, and when. MaxisAI Holarchy governs every request automatically. Before a call reaches a model, it grounds the request in the organization’s own standards, SOPs, prior decisions, and live study data, and masks protected data, so the model never sees it. After the model responds, it scores the output against the organization’s quality bar and the regulator’s rules, routes what falls short to a human reviewer, and seals the path into a signed, immutable record.
What distinguishes MaxisAI Holarchy is that industry knowledge, standards, and compliance are built into the fabric itself, so each decision traces back to the clause it answers to. Governance is not added after the fact. It is where the product begins. This institutional memory also compounds when a reviewer corrects an output, that correction becomes the next answer, so quality rises and cost falls over time. Within the Holarchy, work is organized into domain-specific intelligences, called MaxisAI Holons, each acting on its own work but never unilaterally, under a single regime of governance, evidence, and human oversight.
In a 90-day benchmarking implementation on a client’s live studies, one synopsis-to-USDM protocol agent was run in two arms, ungoverned without context layer and another grounded through the Context Layer, both measured identically; and Context Layer grounding excelled. Against a 26-run ungoverned baseline, the governed arm cut cost per run by 36 percent, raised quality from 83.6 to 93.0 percent and confidence from 87.1 to 94.5 percent, and avoided 94 issues that would otherwise have reached a reviewer or an inspection. Because each run and each correction is written back as institutional memory, the advantage compounded over time rather than settling.
“Most AI systems treat governance as something you add on afterwards. We built it into the fabric, so industry standards, the regulator’s rules, and each organization’s own knowledge collectively serve as memory behind every call,” said Rajesh Majji, VP, Product and Technology at Maxis AI. “And every human correction becomes the next answer, so quality compounds while cost comes down.”
Availability
MaxisAI Holarchy is in production use by early adopter customers, available as an independent product or as a layer within the MaxisAI platform. Organizations can run it three ways: shared, with Maxis AI hosting the fabric and the data; external, with Maxis AI running the services while the organization’s databases hold the data; and private, entirely inside the organization’s own datacenter. It is being launched first for clinical research and life sciences and is built to extend across other regulated industries and geographies by its ability to manage sovereign context.
To learn more or request a briefing, visit MaxisAI Holarchy or contact [email protected].
About Maxis AI
Maxis AI is the first AI Workforce for Clinical Trials, delivering a supervised execution layer purpose-built for regulated clinical environments. The company’s enterprise-ready Agentic AI platform is “Designed to Think. Built to Act.” pairing governed AI agents with expert human oversight across study startup, enrollment, data management, statistical programming, medical writing, and risk oversight. Built on the foundation of more than 3,300 clinical trials of execution experience, it integrates with existing systems of record while maintaining full observability, audit traceability, explainability, and reproducibility. Maxis AI serves pharma, biotech, medical devices, and CROs of all sizes. Learn more at maxisai.com.
Contacts
Maxis AI
510 Thornall Street, Suite 180 Edison, NJ 08837, USA
Moulik Shah, Founder and CEO
[email protected]
Press/Media:
Sneha Gupta, Corporate Communications and Marketing, Maxis AI
[email protected]
